Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 4 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2021 Filed Dec 14, 2021 22:36 UTC |
Vaddi KrishnaDirector · President, CEO
|
GrantCommon Stock | 8,000 | $12.13 | $97,035.20 |
DisclosureSEC source: 0001209191-21-069547 · doc4.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,519 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.01 to $12.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:21 UTC |
Combs AndrewEVP, Head of Chemistry
|
PurchaseCommon Stock | 4,000 | $12.12 | $48,480.00 |
DisclosureSEC source: 0001209191-21-069796 · doc4.xml · nonDerivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,380 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:00 UTC |
Chardonnet LaurentChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001209191-21-067324 · doc4.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2031-11-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on November 29, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:42 UTC |
Morosini DeborahEVP, Chief of Clinical Affairs
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 28,751 | $0.00 Strike: $12.85 | $0.00 |
DisclosureSEC source: 0001209191-21-065616 · doc4.xml · derivative · entry 4 Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,045 Underlying: Common Stock · 28,751 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:42 UTC |
Morosini DeborahEVP, Chief of Clinical Affairs
|
SaleCommon Stock | 400 | $16.43 | $6,570.00 |
DisclosureSEC source: 0001209191-21-065616 · doc4.xml · nonDerivative · entry 3 Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:42 UTC |
Morosini DeborahEVP, Chief of Clinical Affairs
|
SaleCommon Stock | 28,351 | $15.87 | $449,961.56 |
DisclosureSEC source: 0001209191-21-065616 · doc4.xml · nonDerivative · entry 2 Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 844 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $16.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:42 UTC |
Morosini DeborahEVP, Chief of Clinical Affairs
|
Exercise / conversionCommon Stock | 28,751 | $12.85 | $369,450.35 |
DisclosureSEC source: 0001209191-21-065616 · doc4.xml · nonDerivative · entry 1 Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 22:56 UTC |
Sandor VictorDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 8,022 | $0.00 Strike: $15.81 | $0.00 |
DisclosureSEC source: 0001209191-21-060506 · doc4.xml · derivative · entry 1 Sandor Victor · CIK 0001620368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,022 Underlying: Common Stock · 8,022 shares Expires 2031-10-12 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly beginning on November 13, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 18:02 UTC |
Mauro David JChief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-059850 · doc4.xml · derivative · entry 5 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,610 Underlying: Common Stock · 15,000 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 18:02 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 1,289 | $32.06 | $41,330.11 |
DisclosureSEC source: 0001209191-21-059850 · doc4.xml · nonDerivative · entry 4 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 18:02 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 7,803 | $31.30 | $244,257.31 |
DisclosureSEC source: 0001209191-21-059850 · doc4.xml · nonDerivative · entry 3 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.87 to $31.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 18:02 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 5,908 | $30.26 | $178,762.49 |
DisclosureSEC source: 0001209191-21-059850 · doc4.xml · nonDerivative · entry 2 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,092 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 18:02 UTC |
Mauro David JChief Medical Officer
|
Exercise / conversionCommon Stock | 15,000 | $1.89 | $28,350.00 |
DisclosureSEC source: 0001209191-21-059850 · doc4.xml · nonDerivative · entry 1 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:53 UTC |
Mauro David JChief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-055307 · doc4.xml · derivative · entry 5 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,610 Underlying: Common Stock · 15,000 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:53 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 4,640 | $37.79 | $175,334.46 |
DisclosureSEC source: 0001209191-21-055307 · doc4.xml · nonDerivative · entry 4 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:53 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 2,873 | $36.92 | $106,080.93 |
DisclosureSEC source: 0001209191-21-055307 · doc4.xml · nonDerivative · entry 3 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,640 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $37.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:53 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 7,487 | $35.91 | $268,867.15 |
DisclosureSEC source: 0001209191-21-055307 · doc4.xml · nonDerivative · entry 2 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,513 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:53 UTC |
Mauro David JChief Medical Officer
|
Exercise / conversionCommon Stock | 15,000 | $1.89 | $28,350.00 |
DisclosureSEC source: 0001209191-21-055307 · doc4.xml · nonDerivative · entry 1 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC |
Pierce ChristopherEVP and Chief of Business Oper
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $12.85 | $0.00 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · derivative · entry 5 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,796 Underlying: Common Stock · 17,000 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC |
Pierce ChristopherEVP and Chief of Business Oper
|
SaleCommon Stock | 6,930 | $42.50 | $294,506.98 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 4 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC |
Pierce ChristopherEVP and Chief of Business Oper
|
SaleCommon Stock | 6,727 | $41.52 | $279,288.90 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 3 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,680 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC |
Pierce ChristopherEVP and Chief of Business Oper
|
SaleCommon Stock | 3,343 | $40.29 | $134,696.82 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 2 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC |
Pierce ChristopherEVP and Chief of Business Oper
|
Exercise / conversionCommon Stock | 17,000 | $12.85 | $218,450.00 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,014 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · derivative · entry 8 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,018 Underlying: Common Stock · 6,014 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 607 | $37.08 | $22,505.19 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 6 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 2,707 | $36.23 | $98,085.44 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,527 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 2,700 | $35.32 | $95,376.69 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,234 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,014 | $1.43 | $8,600.02 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · derivative · entry 7 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,032 Underlying: Common Stock · 1,700 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 1,700 | $35.19 | $59,819.43 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 21:16 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,700 | $1.43 | $2,431.00 |
DisclosureSEC source: 0001209191-21-053867 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:02 UTC |
Piper BrianChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-053758 · doc4.xml · derivative · entry 5 Piper Brian · CIK 0001665924 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,329 Underlying: Common Stock · 8,333 shares Expires 2029-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on July 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:02 UTC |
Piper BrianChief Financial Officer
|
SaleCommon Stock | 2,344 | $34.33 | $80,469.29 |
DisclosureSEC source: 0001209191-21-053758 · doc4.xml · nonDerivative · entry 4 Piper Brian · CIK 0001665924 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.82 to $34.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:02 UTC |
Piper BrianChief Financial Officer
|
SaleCommon Stock | 3,889 | $33.23 | $129,234.58 |
DisclosureSEC source: 0001209191-21-053758 · doc4.xml · nonDerivative · entry 3 Piper Brian · CIK 0001665924 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,344 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.78 to $33.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:02 UTC |
Piper BrianChief Financial Officer
|
SaleCommon Stock | 2,100 | $32.44 | $68,123.58 |
DisclosureSEC source: 0001209191-21-053758 · doc4.xml · nonDerivative · entry 2 Piper Brian · CIK 0001665924 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,233 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.77 to $32.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:02 UTC |
Piper BrianChief Financial Officer
|
Exercise / conversionCommon Stock | 8,333 | $1.89 | $15,749.37 |
DisclosureSEC source: 0001209191-21-053758 · doc4.xml · nonDerivative · entry 1 Piper Brian · CIK 0001665924 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,728 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · derivative · entry 5 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,732 Underlying: Common Stock · 1,728 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 558 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · derivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,672 Underlying: Common Stock · 558 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 2,286 | $35.07 | $80,161.33 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,728 | $1.43 | $2,471.04 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:44 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionCommon Stock | 558 | $1.89 | $1,054.62 |
DisclosureSEC source: 0001209191-21-051885 · doc4.xml · nonDerivative · entry 1 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:26 UTC |
Mauro David JChief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-050404 · doc4.xml · derivative · entry 6 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,610 Underlying: Common Stock · 15,000 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:26 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 100 | $32.63 | $3,263.00 |
DisclosureSEC source: 0001209191-21-050404 · doc4.xml · nonDerivative · entry 5 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:26 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 6,721 | $32.15 | $216,051.25 |
DisclosureSEC source: 0001209191-21-050404 · doc4.xml · nonDerivative · entry 4 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:26 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 2,063 | $31.03 | $64,010.35 |
DisclosureSEC source: 0001209191-21-050404 · doc4.xml · nonDerivative · entry 3 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,821 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.60 to $31.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:26 UTC |
Mauro David JChief Medical Officer
|
SaleCommon Stock | 6,116 | $29.93 | $183,069.62 |
DisclosureSEC source: 0001209191-21-050404 · doc4.xml · nonDerivative · entry 2 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,884 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.35 to $30.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:26 UTC |
Mauro David JChief Medical Officer
|
Exercise / conversionCommon Stock | 15,000 | $1.89 | $28,350.00 |
DisclosureSEC source: 0001209191-21-050404 · doc4.xml · nonDerivative · entry 1 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC |
Scherle PeggyChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · derivative · entry 4 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,460 Underlying: Common Stock · 20,000 shares Expires 2028-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 680 | $36.09 | $24,539.98 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · nonDerivative · entry 3 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,920 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 23:27 UTC |
Scherle PeggyChief Scientific Officer
|
SaleCommon Stock | 19,320 | $35.45 | $684,839.90 |
DisclosureSEC source: 0001209191-21-048688 · doc4.xml · nonDerivative · entry 2 Scherle Peggy · CIK 0001824632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,600 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.